Adagio Medical vs Orchestra BioMed
ADGM and OBIO side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADGM and OBIO compare
Orchestra BioMed is the larger company, worth 299 times as much as Adagio Medical ($428M against $1.4M).
Orchestra BioMed scores higher on the StockData Score (9 against 2 for Adagio Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADGM | OBIO |
|---|---|---|
| Size and price | ||
| Market cap | $1.4M | $428M |
| Share price | $1.61 | $7.12 |
| Change, 1 year | 97.4% | 70.3% |
| Change, 5 years | −99.5% | −27.8% |
| Beta (5Y) | – | 1.12 |
| Employees | 41 | 86 |
| StockData Score | ||
| Total score | 2 | 9 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 1 | 1 |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 13.4× |
| P/B | 0.1× | – |
| FCF yield | −1233% | −13.8% (better) |
| Growth | ||
| Revenue growth (TTM) | – | 986% |
| Profitability | ||
| Gross margin | – | 99.5% |
| Operating margin | – | −181% |
| Net margin | – | −185% |
| FCF margin | – | −185% |
| Return on equity | 9.6% | – |
| Return on invested capital | −314% | – |
| Financial health | ||
| Interest coverage | −5.8× | – |
| Current ratio | 0.90 | 8.26 (better) |
| Altman Z-score | −6.29 | −2.31 (better) |
| Piotroski F-score | – | 6 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | – | 46.1% |
| Held by insiders | – | 56.6% |
| Insider net buying, 12 months | $244K | $6.1M (better) |
| Short interest, % of float | – | 10.5% |
Go deeper
- ADGM stock overview
- ADGM income statement
- ADGM valuation and score
- OBIO stock overview
- OBIO income statement
- OBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.